Compass Therapeutics, Inc. Share Price
Stocks
CMPX
US20454B1044
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
21:00:00 22/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 1.240 USD | -31.87% |
|
-32.97% | -76.91% |
| 09-22 | Sector Update: Healthcare Stocks Rise Late Afternoon | MT |
| 09-22 | Compass Therapeutics Says FDA Recommends New Tovecimig Trial in Biliary Tract Cancer; Shares Fall | MT |
| Market Cap | 223M 195M 183M 167M 314M 21.35B 314M 2.2B 849M 10.9B 839M 820M 35.15B | P/E 2026 * |
-2.5x | P/E 2027 * | -2.26x |
|---|---|---|---|---|---|
| Enterprise Value | 73.31M 64.06M 60.21M 54.95M 103M 7.01B 103M 723M 279M 3.58B 275M 269M 11.54B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 4.89x |
| Free-Float |
87.55% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| CMPX | Delayed | |
CBOE
| CMPX | Real-time |
Last Transcript: Compass Therapeutics, Inc.
| 1 day | -31.87% | ||
| 1 week | -32.97% | ||
| Current month | -48.12% | ||
| 1 month | -48.33% | ||
| 3 months | -40.95% | ||
| 6 months | -75.92% | ||
| Current year | -76.91% |
| 1 week | 1.15 |  | 1.94 |
| 1 month | 1.15 | | 2.55 |
| Current year | 1.15 | | 6.88 |
| 1 year | 1.15 | | 6.88 |
| 3 years | 0.76 | | 6.88 |
| 5 years | 0.76 | | 6.88 |
| 10 years | 0.76 | | 11 |
| Manager | Title | Age | Since |
|---|---|---|---|
Thomas Schuetz
CEO | Chief Executive Officer | 65 | 27/05/2024 |
Barry Shin
DFI | Director of Finance/CFO | 54 | 08/12/2024 |
Bing Gong
CTO | Chief Tech/Sci/R&D Officer | 50 | 31/12/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Schuetz
BRD | Director/Board Member | 65 | 31/12/2013 |
Phil Ferneau
BRD | Director/Board Member | 64 | 31/12/2014 |
Carl Gordon
CHM | Chairman | 61 | 31/12/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 29/04/26 | Buy | Controller/Auditor | 15,000 | 0.0083% | ||
| 29/04/26 | Buy | General Counsel | 25,000 | 0.0139% | ||
| 29/04/26 | Free | Controller/Auditor | 15,000 | 0.0083% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -31.87% | -32.97% | -64.47% | -36.73% | 223M | |
| -0.07% | +7.14% | +53.95% | +111.00% | 74.27B | |
| -0.21% | +0.64% | +36.20% | +78.96% | 61.21B | |
| 0.00% | +5.33% | +33.16% | +20.37% | 27.55B | |
| -0.15% | +0.75% | -16.69% | +361.67% | 26.38B | |
| +2.93% | +4.32% | +2.18% | -3.60% | 25.34B | |
| +1.43% | +4.52% | +26.63% | -8.33% | 20.84B | |
| -1.43% | +4.91% | -5.90% | +519.88% | 14.94B | |
| +0.87% | -3.73% | +159.95% | +327.53% | 15.17B | |
| +1.63% | +2.20% | +46.92% | +170.72% | 14.41B | |
| Average | -2.69% | -0.44% | +27.19% | +154.15% | 28.03B | |
| Weighted average by Cap. | +0.33% | +3.41% | +36.77% | +135.92% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 18.47M 16.14M 15.17M 13.84M 25.98M 1.77B 25.99M 182M 70.26M 902M 69.37M 67.85M 2.91B |
| Net income | -93.27M -81.5M -76.6M -69.91M -131M -8.92B -131M -919M -355M -4.55B -350M -343M -14.68B | -110M -96.02M -90.24M -82.35M -155M -10.5B -155M -1.08B -418M -5.36B -413M -404M -17.29B |
| Net Debt | -150M -131M -123M -112M -211M -14.34B -211M -1.48B -571M -7.32B -563M -551M -23.61B | -133M -116M -109M -99.69M -187M -12.71B -187M -1.31B -506M -6.49B -499M -489M -20.93B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/09/26 | US$1.240 | -31.87% | 27,202,788 |
| 21/09/26 | US$1.820 | -4.21% | 2,987,340 |
| 18/09/26 | US$1.900 | +2.70% | 8,210,036 |
| 17/09/26 | US$1.850 | +1.09% | 2,515,917 |
| 16/09/26 | US$1.830 | -1.08% | 2,242,999 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CMPX Stock
Select your edition
All financial news and data tailored to specific country editions
